Vetr upgraded shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a buy rating in a report issued on Wednesday, December 20th. The firm currently has $147.14 price objective on the stock.
JNJ has been the subject of a number of other reports. Citigroup increased their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a buy rating in a research report on Monday, October 23rd. Zacks Investment Research cut shares of Johnson & Johnson from a buy rating to a hold rating in a research report on Tuesday, December 12th. BMO Capital Markets raised their price objective on shares of Johnson & Johnson to $161.00 and gave the stock an outperform rating in a research report on Tuesday, December 12th. Leerink Swann reaffirmed an outperform rating and set a $165.00 target price (up previously from $150.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Finally, Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an outperform rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson presently has a consensus rating of Hold and an average target price of $145.94.
Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Wednesday. The stock has a market cap of $391,590.00, a P/E ratio of 25.31, a price-to-earnings-growth ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $146.42.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the firm earned $1.68 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a dividend yield of 2.31%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
Institutional investors have recently added to or reduced their stakes in the stock. Harding Loevner LP acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. increased its position in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. Mountain Capital Investment Advisors Inc acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Johnson & Johnson during the 2nd quarter worth approximately $177,000. Institutional investors and hedge funds own 65.70% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.